DC Advisory advises Montagu and its portfolio company, RTI Surgical on the acquisition of Collagen Solutions

Background

• RTI Surgical (RTI) is a leading regenerative medicine-focused Contract Development and Manufacturing Organization (CDMO) with expertise in tissue engineering and a strong allograft portfolio as well as a growing xenograft portfolio
• RTI partners with Original Equipment Manufacturers (OEMs) to help identify clinical problems and develop customized solutions that promote healing, accelerate recovery and prevent surgical complications
• RTI is a portfolio company of Montagu Private Equity (Montagu), based in London, United Kingdom with $12+ billion in assets under management
• Collagen Solutions (CS) is an integrated biomaterials CDMO and tissue supply and procurement company, specializing in bovine and porcine biomaterials and cardiac technologies

Process

• DC Advisory served as the exclusive financial advisor for RTI and Montagu in this transaction
• DC Advisory guided RTI through a competitive process by helping differentiate themselves through extensive upfront diligence and identifying value creation and synergy opportunities
• DC Advisory provided M&A advisory and execution support services, including M&A process strategy, sector insights and support in process negotiation and transaction documentation

Outcome

• The transaction is expected to close in the next few weeks and the closing is subject to customary closing conditions

• CS expands RTI’s xenograft tissue portfolio through bovine and porcine collagen materials while bringing specialized and complementary capabilities as well as expertise in soft tissue engineering and cardiac applications

• The acquisition increases access to high-growth therapeutic areas, including cardiac care, sports medicine, orthopaedic surgery and plastic and reconstructive surgery, resulting in expansion of RTI’s overall market presence

• The acquisition presents a significant opportunity to accelerate development of innovative biomaterials through combination products, thereby enhancing RTI's ability to collaborate with OEM customers.
• RTI and CS’ partnership aims to address patient needs more effectively and improve patient outcomes